Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRani Therapeutics Holdings Inc

Rani Therapeutics Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.568 USD 0.01 ( 1.41%)
Last update at 2026-11-11T21:00:00Z
VOLUME
334757
Market Cap
115.44M

Momentum Score

…

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.55
Low
0.58
High
52 Week Price Range
0.45
Low
3.87
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.56
Dividend Yield
-
Revenue TTM
4.88M
Revenue Per Share
0.04
Gross Profit TTM
4.88M
Debt / Equity
0.13
ROE
-172.15%
Net Debt
-14.30M
ROCE
-82.82%
Diluted EPS TTM
-0.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -40.95M -30.02M -67.88M -63.27M -53.05M
Minority interest 11.28M 26.57M 35.51M -32.76M 44.76M
Net income -29.67M -30.02M -33.97M -63.34M -53.09M
Selling general administrative 19.74M 23.95M 26.48M 26.84M 27.83M
Selling and marketing expenses - - 0.82M - -
Gross profit 0.73M 1.03M -0.82M - 2.72M
Reconciled depreciation 0.90M 1.03M 0.77M 0.55M 0.50M
Ebit -38.06M -51.55M -62.80M -63.45M -51.60M
Ebitda -37.16M -50.52M -61.98M -62.20M -51.51M
Depreciation and amortization 0.90M 1.03M 0.82M 1.25M 0.09M
Non operating income net other - - - 1.25M -
Operating income -38.31M -53.31M -66.10M -63.45M -51.60M
Other operating expenses 39.94M 54.34M 66.10M 63.45M 54.32M
Interest expense 2.89M 5.03M 5.08M 1.07M 0.47M
Tax provision - - -0.04M 0.07M 0.04M
Interest income 0.83M 1.76M 3.44M 1.25M 0.09M
Net interest income -2.06M -3.27M -1.06M 0.18M -0.38M
Income tax expense - 26.57M -33.91M 0.07M 0.04M
Total revenue 1.63M 1.03M 0.00M 0.00M 2.72M
Total operating expenses 39.04M 54.34M 65.28M 63.45M 54.32M
Cost of revenue 0.90M - 0.82M - -
Total other income expense net -2.64M 23.30M -1.78M 0.18M -1.45M
Net income from continuing ops -40.95M -56.58M -71.17M -63.34M -53.09M
Net income applicable to common shares - - - -61.18M -8.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 58.62M 36.63M 57.92M 108.03M 124.21M
Other current assets 1.57M 1.68M 1.31M 1.94M 2.14M
Total liab 17.11M 33.14M 32.47M 34.02M 2.64M
Total stockholder equity 33.01M 1.99M 12.87M 36.85M 47.41M
Other current liab 3.94M 2.07M 1.73M 2.35M 1.56M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -132.58M -102.91M -72.89M -38.92M -8.33M
Other assets - - 0.00M - -
Cash 18.62M 3.76M 6.36M 27.01M 117.45M
Total current liabilities 12.67M 19.89M 7.99M 4.82M 2.64M
Current deferred revenue 6.83M -1.46M - - -
Net debt -14.30M 25.95M 23.73M 3.21M -117.45M
Short term debt 1.59M 16.46M 5.62M 1.01M -
Short long term debt - 15.00M 4.90M - -
Short long term debt total 4.32M 29.71M 30.10M 30.21M -
Other stockholder equity 165.58M 104.89M 85.76M 75.84M 55.74M
Property plant equipment - - - 6.04M 4.61M
Total current assets 53.32M 29.74M 50.55M 100.92M 119.59M
Net tangible assets - - - 36.85M 47.41M
Short term investments 31.09M 23.88M 42.67M 71.47M -
Net receivables 2.04M 0.43M 0.20M - -
Long term debt - 9.61M 24.48M 29.15M -
Accounts payable 0.31M 1.36M 0.65M 1.46M 1.08M
Noncontrolling interest in consolidated entity - - - 37.15M -
Accumulated other comprehensive income 0.00M 0.01M -0.01M -0.07M -124.21M
Common stock total equity - - - 0.01M -
Retained earnings total equity - - - -38.92M -
Non currrent assets other 0.25M 0.25M 0.55M 1.06M -
Non current assets total 5.30M 6.89M 7.37M 7.10M 4.61M
Capital lease obligations 4.32M 5.10M 0.72M 1.06M -
Long term debt total - - - 29.15M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -6.94M 19.81M 16.13M -70.82M -0.51M
Change to liabilities - - - 0.77M -2.17M
Total cashflows from investing activities -7.03M 19.81M 29.86M -72.44M -0.51M
Net borrowings -20.72M -5.00M 0.00M 29.57M -4.57M
Total cash from financing activities 40.30M 13.59M 0.23M 29.00M 77.15M
Change to operating activities - - - - -1.25M
Net income -29.67M -56.58M -33.97M -63.34M -53.09M
Change in cash 14.56M -2.10M -21.14M -89.95M 44.40M
Begin period cash flow 4.26M 6.36M 27.51M 117.45M 73.06M
End period cash flow 18.82M 4.26M 6.36M 27.51M 117.45M
Total cash from operating activities -18.71M -35.50M -51.24M -46.52M -32.24M
Issuance of capital stock 52.60M 18.26M 0.00M 0.00M 79.97M
Depreciation 0.90M 1.03M 0.82M 0.55M 0.50M
Other cashflows from investing activities 0.28M 1.25M - - -
Change to account receivables -1.61M -0.43M - - -
Sale purchase of stock - 0.30M -0.00M 0.27M -
Other cashflows from financing activities -0.06M -0.05M -0.16M 28.73M 8.07M
Change to netincome - - - 15.78M -20.98M
Capital expenditures 0.09M 0.27M 1.23M 1.62M 0.51M
Cash flows other operating - - - 0.51M -
Cash and cash equivalents changes - - - -89.95M -
Change in working capital 6.96M -0.54M -2.14M 0.51M -3.43M
Stock based compensation 11.80M 16.03M 19.01M 15.78M 22.59M
Other non cash items -8.70M 4.57M -34.96M -0.01M 0.11M
Free cash flow -18.80M -35.76M -52.47M -48.13M -32.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RANI
Rani Therapeutics Holdings Inc		 0.01
1.41%		 0.57 - - 23.67 2.48 9.70 -1.42
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

2051 Ringwood Avenue, San Jose, CA, United States, 95131

408 457 3700

https://www.ranitherapeutics.com

69

Name Title Year Born
Mr. Mir A. Imran Exec. Chairman 1956
Mr. Talat Imran CEO & Director 1981
Mr. Svai S. Sanford Chief Financial Officer 1970
Dr. Mir Hashim Chief Scientific Officer 1960
Mr. Eric Groen Gen. Counsel NA
Ms. Bella Vazquez VP of HR NA
Mr. Mir A. Imran Executive Chairman 1956
Mr. Talat Imran CEO & Director 1982
Mr. Eric Groen General Counsel 1971
Ms. Bella Vazquez Vice President of Human Resources NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…